ClinicalTrials.gg
TerminatedNCT02999633ISLAYUpdated Mar 21, 2022Results posted

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

A Phase 2 interventional study of Isatuximab SAR650984 and dexamethasone in T-cell Type Acute Leukemia-Precursor and T-lymphoblastic Lymphoma/Leukaemia, sponsored by Sanofi. Terminated at 17 sites in 7 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2022-03-21.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to an unsatisfactory benefit/risk ratio, as specified in \& 14.8.1 of the protocol, Sanofi decided to stop enrollment and terminate ACT14596 prematurely

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in France — 3 open to participants now, 5 under way, 1 of them phase 3. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · France.

Enrollment
17th of 18
14 · median 43
Started
2017
with 2 others
Phase 2
5 of 23
none open now
Registered
14th of 23
by date

Among the 23 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in France, this one is the 17th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2017, is one of 5 in phase 2, and was the 14th registered.

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

420 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 75 are open to participants now.

Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

3 of the 23 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 59 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 24 (41%) set no upper age limit and 30 (51%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in France, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of isatuximab.

Secondary Objectives:

  • To evaluate the safety profile of isatuximab.
  • To evaluate the duration of response (DOR).
  • To evaluate progression free survival (PFS) and overall survival (OS).
  • To evaluate the pharmacokinetics (PK) of isatuximab in participants with T-ALL or T-LBL.
  • To evaluate immunogenicity of isatuximab in participants with T-ALL or T-LBL.
  • To assess minimal residual disease (MRD) and correlate it with clinical outcome.
Read the detailed description

The study duration per participant included a 3-week screening period, an approximately 1 year of treatment period or until disease progression or discontinuation for any other reason, and a follow-up period of at least 30 days after the last investigational medicinal product administration.

03

Conditions studied

  • T-cell Type Acute Leukemia-Precursor
  • T-lymphoblastic Lymphoma/Leukaemia
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must had a known diagnosis of acute lymphoblastic leukemia (ALL) of T cell origin, including T-LBL and T-ALL with extramedullary involvement at relapse confirmed by .
  • Participants must be previously treated for T-ALL or T-LBL and have or are refractory to most recent treatment. Participants in first relapse were be eligible regardless of the first remission duration.
  • Participants must had been previously exposed to nelarabine in countries where this drug is available (unless due to a to its use or administrative issue).
  • No more than 3 prior salvage therapies.

Exclusion criteria

Exclusion criteria:

  • Prior treatment with immunotherapy/ agents within 3 weeks, chemotherapy within 2 weeks of study treatment. Must have recovered from acute toxicity before first study treatment administration.
  • Prior stem cell transplant within 4 months and/or evidence of active systemic and/or therapy for Graft versus Host Disease within 1 week before the first study treatment administration.
  • Clinical evidence of active central nervous system (CNS) leukemia.
  • T-ALL with testicular involvement alone.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Isatuximab

    Participants received intravenous administration of isatuximab at a dose of 20 milligrams/kilogram (mg/kg) at Day 1, 8, 15 and 22 of each Cycle (up to 2 treatment cycles, each cycle 28 days).

    Drug: Isatuximab SAR650984 · Drug: dexamethasone · Drug: acetaminophen · Drug: ranitidine · Drug: diphenhydramine

Interventions

  • Pharmaceutical form:solution Route of administration: intravenous

  • Pharmaceutical form:pills Route of administration: oral

  • Pharmaceutical form:solution Route of administration: intravenous

  • Pharmaceutical form:pills Route of administration: oral

  • Pharmaceutical form:solution Route of administration: intravenous

  • Pharmaceutical form:solution Route of administration: intravenous

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response

    Objective response was defined as percentage of participants with complete response (CR) or with complete response with incomplete peripheral recovery (CRi) as per National Comprehensive Cancer Network (NCCN) guidelines. CR was defined as no circulating blasts or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement, trilineage hematopoiesis and less than 5 percentage blasts, absolute neutrophil count (ANC) greater than 1000 per micro liter, platelets less than 100 000 per micro liter, no recurrence for 4 weeks. CRi meet all criteria for complete response except platelet count and/or ANC.

    Time frame: Baseline until disease progression or death (maximum duration: 12.1 weeks)

Secondary outcomes

  1. Duration of Response (DOR)

    DOR defined as time (in days) from date of first response until date of first documented progressive disease (PD) or death (from any cause), whichever came first. Progressive disease as per NCCN guidelines was defined as increase of at least 25 percentage (%) in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.

    Time frame: Baseline until disease progression or death (maximum duration: 12.1 weeks)

  2. Progression Free Survival (PFS)

    PFS was defined as the time interval (in days) from the date of first study drug administration to the date of first observation of PD or death due to any cause, whichever came first. PD as per NCCN guidelines was defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.

    Time frame: Baseline until disease progression or death (maximum duration: 12.1 weeks)

  3. Overall Survival (OS)

    Overall Survival was defined as the time interval from the date of first study drug administration to the date of death due to any cause.

    Time frame: Baseline until death (maximum duration: 12.1 weeks)

  4. Number of Participants With Minimal Residual Disease (MRD)

    Presence of MRD was measured by sequencing and/or flow cytometry in participants achieving CR and CRi. CR was defined as no circulating blasts or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement, trilineage hematopoiesis and less than 5 percentage blasts, ANC greater than 1000 per micro liter, platelets less than 100 000 per micro liter, no recurrence for 4 weeks. Complete response with incomplete blood count recovery meet all criteria for complete response except platelet count and/or ANC.

    Time frame: Baseline until death or study cut-off (maximum duration: 12.1 weeks)

07

Results

Posted Jan 18, 2020

Participant flow

The study was conducted in 6 countries. A total of 16 participants were screened of those 2 participants failed screening: 1 participant for evidence of ongoing infection and 1 participant for not meeting the criterion for relapsed or refractory T-acute lymphoblastic leukemia (ALL)/T-lymphoblastic lymphoma (LBL).

Participant flow — Overall Study
MilestoneIsatuximab
Started14
Completed0
Not completed14
Withdrew: Adverse event2
Withdrew: Progressive disease12

Outcome measures

PrimaryPercentage of Participants With Objective Response

Objective response was defined as percentage of participants with complete response (CR) or with complete response with incomplete peripheral recovery (CRi) as per National Comprehensive Cancer Network (NCCN) guidelines. CR was defined as no circulating blasts or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement, trilineage hematopoiesis and less than 5 percentage blasts, absolute neutrophil count (ANC) greater than 1000 per micro liter, platelets less than 100 000 per micro liter, no recurrence for 4 weeks. CRi meet all criteria for complete response except platelet count and/or ANC.

Time frame:
Baseline until disease progression or death (maximum duration: 12.1 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response
percentage of participantsIsatuximab
Percentage of Participants With Objective Response0 (0 to 23.2)
SecondaryDuration of Response (DOR)

DOR defined as time (in days) from date of first response until date of first documented progressive disease (PD) or death (from any cause), whichever came first. Progressive disease as per NCCN guidelines was defined as increase of at least 25 percentage (%) in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.

Time frame:
Baseline until disease progression or death (maximum duration: 12.1 weeks)

No measurements were reported for this outcome.

SecondaryProgression Free Survival (PFS)

PFS was defined as the time interval (in days) from the date of first study drug administration to the date of first observation of PD or death due to any cause, whichever came first. PD as per NCCN guidelines was defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.

Time frame:
Baseline until disease progression or death (maximum duration: 12.1 weeks)

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

Overall Survival was defined as the time interval from the date of first study drug administration to the date of death due to any cause.

Time frame:
Baseline until death (maximum duration: 12.1 weeks)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Minimal Residual Disease (MRD)

Presence of MRD was measured by sequencing and/or flow cytometry in participants achieving CR and CRi. CR was defined as no circulating blasts or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement, trilineage hematopoiesis and less than 5 percentage blasts, ANC greater than 1000 per micro liter, platelets less than 100 000 per micro liter, no recurrence for 4 weeks. Complete response with incomplete blood count recovery meet all criteria for complete response except platelet count and/or ANC.

Time frame:
Baseline until death or study cut-off (maximum duration: 12.1 weeks)

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to 30 days after last dose of study drug administration (up to maximum of 12.1 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Isatuximab6/14 (42.9%)10/14 (71.4%)12/14 (85.7%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventIsatuximab
Disease ProgressionGeneral disorders4/14
Acute Myocardial InfarctionCardiac disorders1/14
Pericarditis ConstrictiveCardiac disorders1/14
PancreatitisGastrointestinal disorders1/14
Device Related InfectionInfections and infestations1/14
Fungal InfectionInfections and infestations1/14
Periorbital CellulitisInfections and infestations1/14
PneumoniaInfections and infestations1/14
SepsisInfections and infestations1/14
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders1/14
Most frequent other events
Showing 10 of 49
Most frequent other events
EventIsatuximab
Infusion Related ReactionInjury, poisoning and procedural complications8/14
PyrexiaGeneral disorders5/14
TachycardiaCardiac disorders2/14
ConstipationGastrointestinal disorders2/14
DiarrhoeaGastrointestinal disorders2/14
Back PainMusculoskeletal and connective tissue disorders2/14
Bone PainMusculoskeletal and connective tissue disorders2/14
CoughRespiratory, thoracic and mediastinal disorders2/14
AnaemiaBlood and lymphatic system disorders1/14
NeutropeniaBlood and lymphatic system disorders1/14

Baseline characteristics

Safety analysis set included all participants who received at least 1 dose of isatuximab.

Age, Continuous
Age, Continuous(years)Isatuximab
Mean41.36 ± 19.30
Sex: Female, Male
Sex: Female, Male(Participants)Isatuximab
Female2
Male12
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Isatuximab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White6
More than one race0
Unknown or Not Reported8
08

Study locations

17 sites
  • Investigational Site Number 8400002
    Atlanta, Georgia 30342, United States
  • Investigational Site Number 8400003
    Hackensack, New Jersey 07601, United States
  • Investigational Site Number 8400001
    Houston, Texas 77030, United States
  • Investigational Site Number 2460001
    Helsinki, 00029, Finland
  • Investigational Site Number 2500005
    Nantes Cedex 01, 44093, France
  • Investigational Site Number 2500001
    Paris Cedex 10, 75475, France
  • Investigational Site Number 2500004
    Pessac, 33600, France
  • Investigational Site Number 2500002
    Pierre Benite, 69310, France
  • Investigational Site Number 3480001
    Budapest, 1083, Hungary
  • Investigational Site Number 3480003
    Budapest, 1097, Hungary
  • Investigational Site Number 3480002
    Debrecen, 4032, Hungary
  • Investigational Site Number 3800001
    Bergamo, 24127, Italy
  • Investigational Site Number 3800004
    Brescia, 25123, Italy
  • Investigational Site Number 4400001
    Vilnius, 08661, Lithuania
  • Investigational Site Number 6430003
    Moscow, 117198, Russian Federation
  • Investigational Site Number 6430004
    Moscow, 125167, Russian Federation
  • Investigational Site Number 6430001
    Moscow, 129301, Russian Federation
09

References and documents

Publications

  • Wang A, Song Z, Zheng G, Nicolazzi C, Fromm JR, Shehu E, Srinivasan S, Chen X, Zhu C, Blondel MC, Adrian FJ. Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2021 Oct;20(10):1916-1925. doi: 10.1158/1535-7163.MCT-21-0058. Epub 2021 Aug 10. PubMed 34376579 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Nov 2017, 8 months.

Results were first posted in Jan 2020, 2 years 2 months after primary completion. A results delay was requested in Nov 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2016
First posted
Dec 21, 2016
StartActual
Mar 8, 2017
Primary completionActual
Nov 14, 2017
CompletionActual
Nov 14, 2017
Results delay requested
Nov 13, 2018
Results first posted
Jan 18, 2020
Last update
Mar 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02999633
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 21, 2016
Start date
Mar 8, 2017
Primary completion
Nov 14, 2017
Completion
Nov 14, 2017
Results posted
Jan 18, 2020
Last update
Mar 21, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion